Nationwide Cancer Incidence in Korea, 2003-2005

Won, Young Joo; Sung, Joohon; Jung, Kyu Won; Kong, Hyun Joo; Park, Sohee; Shin, Hai Rim; Ahn, Yoon Ok; Hwang, In Kyoung; Lee, Dong Hoon; Choi, Jin Su; Kim, Woo Cheol; Lee, Tae Yong; Yoo, Changhee; Bae, Jong Myon; Kim, Ok Nam; Chung, Woojin; Kong, In Sik; Lee, Duk Hyoung; Lee, Jin Soo

doi:10.4143/crt.2009.41.3.122

Cited by 131 publications

(97 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The KNCIDB contains 95% of newly-diagnosed malignancies in Korea. (2) Also excluded were 58 730 otherwise eligible participants with missing values for some of the variables needed for this study. After these exclusions, rescreening behavior was examined in a final study population of 4 060 257 participants.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Who participates in the gastric cancer screening and on‐time rescreening in the National Cancer Screening Program? A population‐based study in Korea

et al. 2011

Self Cite

View full text Add to dashboard Cite

Gastric cancer (GC) screening is a major challenge in countries where the disease is highly prevalent. This study was conducted to identify the factors associated with participation in GC screening and on-time rescreening among the average-risk population in Korea. The study population was derived from the National Cancer Screening Program database. The population for this study was 22 913 618 individuals aged ‡40 years who had been invited to participate in a GC screening program from 2005 to 2006. We determined whether these individuals had attended the GC screening program and which method -an upper gastrointestinal series (UGIS) or endoscopy-they underwent. We followed the participants to determine whether they had a second GC screening after 2 years. The overall participation rate in the GC screening was 20.5%. More people underwent UGIS than endoscopy. Individuals who had been screened by endoscopy rather than UGIS were more likely to be younger, male, or those who were National Health Insurance (NHI) beneficiaries with a higher premium rate. Of those who underwent baseline screening, 59.4% participated in a rescreening program 2 years later. NHI beneficiaries with a higher premium rate were significantly more likely to be rescreened than medical aid recipients. The results from this study showed that the UGIS were more commonly used in organized GC screenings in Korea, and those who underwent UGIS were more likely to return for subsequent screening compared to those who underwent an endoscopy. (Cancer Sci 2011; 102: 2241-2247 G astric cancer (GC) is the fourth most common cancer behind lung cancer, breast cancer, and colorectal cancer, and in 2008 was the second most common cause of cancer deaths worldwide. (1) In Korea, GC is the most frequent type of cancer. (2,3) In countries where GC is highly prevalent, GC screening is offered to the average-risk population to reduce the disease burden. (4) Gastric cancer screening has shown improvements in survival rates as a result of early detection and consequently higher cure rates. (5) Therefore, many Asian countries with a high burden of GC have considered implementing GC screening for the general population. (6) Since 1960, Japan has implemented photofluorography (via an indirect upper gastrointestinal series [UGIS]) screening programs to detect GC in its early stages and prevent GC deaths. (6) The cohort studies conducted in Japan showed a significant GC mortality reduction with photofluorography screening. (5,7) In recent years, endoscopy has replaced photofluorography as the initial mass screening method in several cities in Japan. (8,9) This technique is increasingly useful for GC screening because of its high detection rate. In a study conducted in Niigata, Japan, the detection of GC by endoscopy was 2.7-4.6 times higher than that by direct or indirect UGIS. (10)(11)(12) Recently, Hosokawa et al. (13) reported an approximately 65% reduction in the GC death rate for participants screened with endoscopy. Despite this promising result, direct evidence for t...

show abstract

Section: Methodsmentioning

confidence: 99%

“…(1) In Korea, GC is the most frequent type of cancer. (2,3) In countries where GC is highly prevalent, GC screening is offered to the average-risk population to reduce the disease burden. (4) Gastric cancer screening has shown improvements in survival rates as a result of early detection and consequently higher cure rates.…”

mentioning

confidence: 99%

Who participates in the gastric cancer screening and on‐time rescreening in the National Cancer Screening Program? A population‐based study in Korea

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Pancreatic cancer is the eighth most common malignancy in Korea, and its incidence has increased over the past decade (1). Given the absence of an efficient therapeutic modality, most patients with metastatic pancreatic cancer suffer from debilitating symptoms and have an extremely poor prognosis (2).…”

Section: Introductionmentioning

confidence: 99%

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Kim

Lim

Jang

et al. 2011

Molecular Cancer Therapeutics

133

View full text Add to dashboard Cite

Although erlotinib has become an important therapeutic option in addition to gemcitabine, the high frequency of KRAS mutations in pancreatic cancer probably limits the benefits. We retrospectively studied 136 pancreatic cancer patients with available formalin-fixed paraffin-embedded tumor blocks from 2003 to 2009 to understand the clinical significance of KRAS mutations in pancreatic cancer patients treated with gemcitabine-based chemotherapy. KRAS mutations were analyzed by sequencing codons 12, 13, and 61. In this study, 71 (52.2%) of the 136 pancreatic adenocarcinomas examined harbored a point mutation in codons 12 (n ¼ 70) and 61 (n ¼ 1) of KRAS. KRAS mutation was not associated with clinicopathologic parameters. Patients with KRAS mutations showed a worse response (11.3%) than those with wild-type KRAS (26.2%) and poor survival (mutant KRAS, 5.8 months vs. wild-type KRAS, 8.0 months; P ¼ 0.001). Multivariate analysis revealed good prognostic factors for overall survival as well to moderately differentiated histology (P < 0.001; HR ¼ 0.437, 95% CI: 0.301-0.634), locally advanced disease (P < 0.001; HR ¼ 0.417, 95% CI: 0.255-0.681), response to first-line chemotherapy (P ¼ 0.003; HR ¼ 0.482, 95% CI: 0.297-0.780), and wild-type KRAS (P ¼ 0.001; HR ¼ 0.523, 95% CI: 0.355-0.770). However, the observed survival advantage is derived from the subgroup of patients treated with gemcitabine/erlotinib (9.7 vs. 5.2 months; P ¼ 0.002), whereas no survival difference based on KRAS mutation status is obvious in the other subgroup of patients treated without erlotinib (7.0 vs. 7.0 months; P ¼ 0.121). These results need to be further explored in upcoming prospective studies to provide a rationale for personalized medicine in pancreatic cancer.

show abstract

“…The program has collected statistical data on cancer incidence and mortality (Cho et al, 2007;Jung et al, 2007;Khang and Kim, 2006;Song and Byeon, 2000;Won et al, 2009). However, still the dependency of the cancer incidence and mortality on socioeconomic status has not been sufficiently investigated in Korea.…”

Section: Introductionmentioning

confidence: 99%

The Association between Cancer Incidence and Family Income: Analysis of Korean National Health Insurance Cancer Registration Data

Kim¹,

Kim²,

Jung³

et al. 2012

Asian Pacific Journal of Cancer Prevention

Self Cite

View full text Add to dashboard Cite

Background: Economic status is known to be directly or indirectly related to cancer incidence since it affects accessibility to health-related social resources, preventive medical checkups, and lifestyle. This study investigates the relationship between cancer incidence and family income in Korea. Methods:Using the Korean National Health Insurance cancer registration data in 2009, the relationship between their family income class and cancer risk was analyzed. The age-standardized incidence rates of the major cancers were calculated for men and women separately. After adjusting for age, residential area, and number of family members, cancer risks for major cancers according to family income class were estimated using a logistic regression model. Results: In men, the risk of stomach cancer for Income Class 5 (lowest) was 1.12 times (95% CI 1.02-1.23) higher than that of Income Class 1 (highest), for lung cancer 1.61 times (95% CI 1.43-1.81) higher, for liver cancer 1.22 times (95% CI 1.08-1.37) higher, and for rectal cancer 1.37 times higher (95% CI 1.18-1.59). In women, the risk of stomach cancer for Income Class 5 was 1.22 times higher (95% CI 1.08-1.37) than that for Income Class 1, while for cervical cancer it was 2.47 times higher (95% CI 2.08-2.94). In contrast, in men, Income Class 1 showed a higher risk of thyroid cancer and prostate cancer than that of Income Class 5, while, in women the same was the case for thyroid cancer. Conclusions: The results show the relationship between family income and cancer risk differs according to type of cancer.

show abstract

Nationwide Cancer Incidence in Korea, 2003-2005

Cited by 131 publications

References 4 publications

Who participates in the gastric cancer screening and on‐time rescreening in the National Cancer Screening Program? A population‐based study in Korea

Who participates in the gastric cancer screening and on‐time rescreening in the National Cancer Screening Program? A population‐based study in Korea

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

The Association between Cancer Incidence and Family Income: Analysis of Korean National Health Insurance Cancer Registration Data

Contact Info

Product

Resources

About